Nrg-Gi005- Phase II/III Study Of Circulating Tumor Dna As A Predictive Biomarker In Adjuvant Chemotherapy In Patients With Stage IIa Colon Cancer (Cobra)
Posted Date: Oct 26, 2020
- Investigator: Davendra Sohal
- Specialties: Cancer, Colorectal Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to compare the rate of ctDNA clearance, and progression free survival in "ctDNA detected" patients treated with or without adjuvant chemotherapy following resection of stage IIA colon cancer
Criteria:
To Be Eligible: Must Have Histologically/Pathologically Confirmed Stage Iia Adenocarcinoma Of The Colon, Ecog 0-1, Complete Gross Resection Of The Tumor, Adequate Organ Function, No Metastatic Disease, No Hx Of Organ Transplant, No Other Malignancy Within 5 Years, No Past Or Active Medical Disorder Or Infection That May Impact Participants Safety Or Ability To Adhere To Study Treatment
Keywords:
Colon Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com